Ashish Noronha, PhD
Postdoctoral Scholar
Urology
School of Medicine
As a Postdoctoral Scholar in the Urology department at UCSF, my research has been dedicated to understanding and addressing drug resistance mechanisms in breast cancer and other aggressive tumors.
Show full bio (100 words) Hide full bio
Currently, my research focuses on uncovering novel molecular mechanisms that underlie the emergence of drug-tolerant persister cells, with a specific emphasis on enhancing the efficacy of treatments for ER-positive breast cancer patients. During my research journey, I have co-authored research publications that delve into the intricate interactions between oncoproteins and transcription factors. Additionally, my work has explored the role of targeted therapies and therapeutic antibodies in the context of cancer treatment. Through my work, I have been able to identify potential therapeutic targets and develop strategies aimed at overcoming resistance to existing therapies.
Publications (15)
Top publication keywords:
Lung NeoplasmsCetuximabAmphiregulinComplementarity Determining RegionsProtein Kinase InhibitorsDrug Resistance, NeoplasmNuclear Pore Complex ProteinsTrastuzumabAcrylamidesProto-Oncogene ProteinsType C PhospholipasesTumor Suppressor Protein p53Receptor Protein-Tyrosine KinasesErbB ReceptorsAntineoplastic Agents, Immunological
-
Computational optimization of antibody humanness and stability by systematic energy-based ranking.
Nature biomedical engineering 2023 Tennenhouse A, Khmelnitsky L, Khalaila R, Yeshaya N, Noronha A, Lindzen M, Makowski EK, Zaretsky I, Sirkis YF, Galon-Wolfenson Y, Tessier PM, Abramson J, Yarden Y, Fass D, Fleishman SJ -
AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer.
Cancer discovery 2022 Noronha A, Belugali Nataraj N, Lee JS, Zhitomirsky B, Oren Y, Oster S, Lindzen M, Mukherjee S, Will R, Ghosh S, Simoni-Nieves A, Verma A, Chatterjee R, Borgoni S, Robinson W, Sinha S, Brandis A, Kerr … -
Cross-talk between mutant p53 and p62/SQSTM1 augments cancer cell migration by promoting the degradation of cell adhesion proteins.
Proceedings of the National Academy of Sciences of the United States of America 2022 Mukherjee S, Maddalena M, Lü Y, Martinez S, Nataraj NB, Noronha A, Sinha S, Teng K, Cohen-Kaplan V, Ziv T, Arandkar S, Hassin O, Chatterjee R, Pirona AC, Shreberk-Shaked M, Gershoni A, Aylon Y, Elazar… -
Nucleoporin-93 reveals a common feature of aggressive breast cancers: robust nucleocytoplasmic transport of transcription factors.
Cell reports 2022 Nataraj NB, Noronha A, Lee JS, Ghosh S, Mohan Raju HR, Sekar A, Zuckerman B, Lindzen M, Tarcitano E, Srivastava S, Selitrennik M, Livneh I, Drago-Garcia D, Rueda O, Caldas C, Lev S, Geiger T, … -
Engineered variants of the Ras effector protein RASSF5 (NORE1A) promote anticancer activities in lung adenocarcinoma.
The Journal of biological chemistry 2021 Singh A, Erijman A, Noronha A, Kumar H, Peleg Y, Yarden Y, Shifman JM
Show all (10 more) Hide
-
PD-L1 recruits phospholipase C and enhances tumorigenicity of lung tumors harboring mutant forms of EGFR.
Cell reports 2021 Ghosh S, Nataraj NB, Noronha A, Patkar S, Sekar A, Mukherjee S, Winograd-Katz S, Kramarski L, Verma A, Lindzen M, Garcia DD, Green J, Eisenberg G, Gil-Henn H, Basu A, Lender Y, Weiss S, Oren M, Lotem … -
Host-Dependent Phenotypic Resistance to EGFR Tyrosine Kinase Inhibitors.
Cancer research 2021 Haga Y, Marrocco I, Noronha A, Uribe ML, Nataraj NB, Sekar A, Drago-Garcia D, Borgoni S, Lindzen M, Giri S, Wiemann S, Tsutsumi Y, Yarden Y -
Targeting autocrine amphiregulin robustly and reproducibly inhibits ovarian cancer in a syngeneic model: roles for wildtype p53.
Oncogene 2021 Lindzen M, Ghosh S, Noronha A, Drago D, Nataraj NB, Leitner O, Carvalho S, Zmora E, Sapoznik S, Shany KB, Levanon K, Aderka D, Ramírez BS, Dahlhoff M, McNeish I, Yarden Y -
Time-Resolved Profiling Reveals ATF3 as a Novel Mediator of Endocrine Resistance in Breast Cancer.
Cancers 2020 Borgoni S, Sofyali E, Soleimani M, Wilhelm H, Müller-Decker K, Will R, Noronha A, Beumers L, Verschure PJ, Yarden Y, Magnani L, van Kampen AHC, Moerland PD, Wiemann S -
Inhibition of a pancreatic cancer model by cooperative pairs of clinically approved and experimental antibodies.
Biochemical and biophysical research communications 2019 Maron R, Schechter B, Nataraj NB, Ghosh S, Romaniello D, Marrocco I, Noronha A, Carvalho S, Yarden Y, Sela M -
A Combination of Approved Antibodies Overcomes Resistance of Lung Cancer to Osimertinib by Blocking Bypass Pathways.
Clinical cancer research : an official journal of the American Association for Cancer Research 2018 Romaniello D, Mazzeo L, Mancini M, Marrocco I, Noronha A, Kreitman M, Srivastava S, Ghosh S, Lindzen M, Salame TM, Onn A, Bar J, Yarden Y -
Irreversible modifications of receptor tyrosine kinases.
FEBS letters 2018 Kreitman M, Noronha A, Yarden Y -
An oligoclonal antibody durably overcomes resistance of lung cancer to third-generation EGFR inhibitors.
EMBO molecular medicine 2018 Mancini M, Gal H, Gaborit N, Mazzeo L, Romaniello D, Salame TM, Lindzen M, Mahlknecht G, Enuka Y, Burton DG, Roth L, Noronha A, Marrocco I, Adreka D, Altstadter RE, Bousquet E, Downward J, Maraver A, … -
SILAC identifies LAD1 as a filamin-binding regulator of actin dynamics in response to EGF and a marker of aggressive breast tumors.
Science signaling 2018 Roth L, Srivastava S, Lindzen M, Sas-Chen A, Sheffer M, Lauriola M, Enuka Y, Noronha A, Mancini M, Lavi S, Tarcic G, Pines G, Nevo N, Heyman O, Ziv T, Rueda OM, Gnocchi D, Pikarsky E, Admon A, Caldas … -
Biological implications and therapeutic significance of DNA methylation regulated genes in cervical cancer.
Biochimie 2015 Bhat S, Kabekkodu SP, Noronha A, Satyamoorthy K